Southeastern Medical Oncology Center-Goldsboro

Summary

Southeastern Medical Oncology Center-Goldsboro is a medical facility located in Goldsboro, North Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Southeastern Medical Oncology Center-Goldsboro is involved with conducting 237 clinical trials across 416 conditions. There are 3 research doctors associated with this hospital, such as Samer S. Kasbari, James Atkins, MD, and Nagesh H. Jayaram.

Top PIs

Clinical Trials running at Southeastern Medical Oncology Center-Goldsboro

Cancer

Breast cancer

Esophageal cancer

Lung Cancer

Bladder Cancer

Breast Cancer

Ovarian Cancer

Chronic Lymphocytic Leukemia

Lymphoma

Laryngeal Cancer

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Olanzapine vs Megestrol Acetate

for Cancer-Related Anorexia

This trial tests whether olanzapine or megestrol acetate is better at increasing appetite in patients with advanced cancer. These patients often struggle with eating and weight loss. Both medications aim to make them feel hungrier, helping them eat more and gain weight. Megestrol acetate is known for its effectiveness in increasing appetite in patients with cancer.

Recruiting

2 awards

Phase 3

1 criteria

Text-Based Smoking Cessation Program

for Rural Cancer Survivors

This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.

Recruiting

2 awards

Phase 3